Bupropion hydrobromide and therapeutic applications
View Patent ↗Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
1. A modified release bupropion hydrobromide composition comprising:
a core comprising a therapeutically effective amount of bupropion hydrobromide; and
a controlled release polymeric coat comprising from about 1% to about 12% by weight of tablet dry weight of a water-insoluble polymer and from about 1.5% to about 10% by weight of tablet dry weight of a water-soluble polymer;
wherein said coat at least partially surrounds said core; and
wherein said composition releases bupropion hydrobromide in a first dissolution medium consisting of 0.1 N HCl and 5%-40% v/v ethanol at a rate that is less than or equal to about 1.1 times the rate of release of bupropion hydrobromide from an identical modified release pharmaceutical composition in a second dissolution medium consisting of 0.1 N HCl, measured over a time period of at least from 0 to 2 hours measured using a USP Apparatus I at 75 rpm and at 37±0.5° C.
2. The modified release composition according to claim 1 wherein said composition releases bupropion hydrobromide in a first dissolution medium consisting of 0.1 N HCl and 5%-40% v/v ethanol at a rate that is less than or equal to the rate of release of bupropion hydrobromide from the identical modified release composition in a second dissolution medium consisting of 0.1 N HCl.
3. The modified release composition according to claim 2 wherein the first dissolution medium consists of 0.1 N HCl and 5% v/v ethanol.
4. The modified release composition according to claim 2 wherein the first dissolution medium consists of 0.1 N HCl and 40% v/v ethanol.
5. The modified release composition according to claim 1 wherein the time period is from 0 to 16 hours.
6. The modified release composition according to claim 1 wherein the composition is a tablet comprising 174 mg, 348 mg or 522 mg of bupropion hydrobromide.
7. The modified release bupropion hydrobromide composition according to claim 1 wherein said composition releases bupropion hydrobromide in a dissolution medium consisting of 0.1 N HCl and 40% v/v ethanol at a rate that is less than the rate of release of bupropion hydrochloride from a modified release bupropion hydrochloride composition, in the identical dissolution medium consisting of 0.1 N HCl and 40% v/v ethanol, measured over a time period of at least from 0 to 2 hours measured using a USP Apparatus I at 75 rpm and at 37±0.5° C.;
wherein the modified release bupropion hydrochloride composition comprises:
a core comprising bupropion hydrochloride, in an amount equimolar to the amount of bupropion hydrobromide in the modified release bupropion hydrobromide composition; and
the identical controlled release polymeric coat comprising a water-insoluble polymer and a water-soluble polymer, used in the bupropion hydrobromide composition; and
wherein the coat at least partially surrounds the core of the modified release bupropion hydrochloride composition.
8. A method of reducing alcohol-induced dose dumping of bupropion hydrobromide in a patient comprising administering to a patient the modified release pharmaceutical composition of claim 1 .
9. The method of claim 8 wherein the composition is a tablet comprising 174 mg, 348 mg or 522 mg of bupropion hydrobromide.
10. The modified release composition according to claim 1 , wherein said water insoluble polymer is selected from the group consisting of cellulose ethers, cellulose esters, polyvinyl alcohol, and mixtures thereof.
11. The modified release composition according to claim 1 , wherein said water soluble polymer is selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and mixtures thereof.
12. The modified release composition according to claim 1 wherein said water insoluble polymer is ethyl cellulose.
13. The modified release composition according to claim 1 wherein said water soluble polymer is polyvinylpyrrolidone.
14. The modified release composition according to claim 1 wherein said water insoluble polymer is ethyl cellulose and said water soluble polymer is polyvinylpyrrolidone.
15. A modified release bupropion hydrobromide composition comprising:
a core comprising a therapeutically effective amount of bupropion hydrobromide; and
a controlled release polymeric coat comprising from about 0.5% to about 10% by weight of tablet dry weight of a water-insoluble polymer and from about 1.5% to about 10% by weight of tablet dry weight of a water-soluble polymer;
wherein said coat at least partially surrounds said core; and
wherein said composition releases bupropion hydrobromide in a first dissolution medium consisting of 0.1 N HCl and 5%-40% v/v ethanol at a rate that is less than or equal to about 1.1 times the rate of release of bupropion hydrobromide from an identical modified release pharmaceutical composition in a second dissolution medium consisting of 0.1 N HCl, measured over a time period of at least from 0 to 2 hours measured using a USP Apparatus I at 75 rpm and at 37±0.5° C.